Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
نویسندگان
چکیده
منابع مشابه
Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
BACKGROUND Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with intravenous (IV) infusion. We aimed to quantify active healthcare professional (HCP) time and patient chair time for rituximab SC and IV, including potential time savings. METHODS This n...
متن کاملResults From a Time and Motion Study of Denosumab Subcutaneous Injection and Zoledronic Acid Intravenous Infusion in Patients with Metastatic Bone Disease From Italian Sites.
1 Fondazione IRCCS Policlinico “San Matteo”, Pavia, Italy; 2 Fondazione IRCCS Istituto Nazionale Tumori , Milano, Italy; 3 Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; 4 Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte, Messina, Italy; 5 A.S.L. AT, Asti, Italy; 6 CHU Brugmann, ULB, Brussels, Belgium; 7 Amgen Spa, Milan, Italy; 8 United BioS...
متن کاملA time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer
Within PrefHer (NCT01401166), patients and healthcare professionals (HCPs) preferred subcutaneous (SC) over intravenous (IV) trastuzumab. We undertook a prospective, observational time and motion study to quantify patients' time in infusion chairs and active HCP time in PrefHer. Patients with HER2-positive early breast cancer received four adjuvant cycles of SC trastuzumab (600 mg fixed dose vi...
متن کاملEfficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
Intravenous rituximab plus chemotherapy is standard treatment for diffuse large B-cell lymphoma. A subcutaneous formulation of rituximab is expected to simplify and shorten drug preparation and administration, and to reduce treatment burden. MabEase (clinicaltrials.gov Identifier: 01649856) examined efficacy, safety and patient satisfaction with subcutaneous rituximab plus chemotherapy in treat...
متن کاملRapid-infusion rituximab in lymphoma treatment.
Rituximab (MabThera; Rituxan Roche) is a chimeric human/ murine immunoglobulin G1 monoclonal antibody that binds specifically to the B-cell-surface antigen, CD20. Using the combination of CHOP-R leads to significant improvement in the outcome of elderly patients with diffuse large B-cell lymphoma, with significant survival benefits maintained during a 5-year follow-up [1]. Other studies have be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLOS ONE
سال: 2016
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0157957